Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study

Published:2021-12 Issue:10316 Volume:398 Page:2093-2100
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Barda Noam,Dagan Noa,Cohen Cyrille,Hernán Miguel A,Lipsitch Marc,Kohane Isaac S,Reis Ben Y,Balicer Ran D

Publisher

Elsevier BV

Subject

General Medicine

Reference24 articles.

1. Antibody response to BTN162b2 mRNA vaccination in naïve versus SARS-CoV-2 infected subjects with and without waning immunity;Zipeto;Res Sq,2021

2. SARS-CoV-2 incidence and vaccine escape;Thompson;Lancet Infect Dis,2021

3. Impact of delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK;Pouwels;medRxiv,2021

4. Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant;Lopez Bernal;N Engl J Med,2021

5. Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis;Ducloux;Kidney Int,2021

Cited by 775 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Case-cohort design as an efficient approach to evaluating COVID-19 vaccine effectiveness, waning, heterologous immune effect and optimal dosing interval;Vaccine;2024-11

2. Science-based exit from stringent countermeasures against COVID-19: Mortality prediction using immune landscape between 2021 and 2022 in Japan;Vaccine: X;2024-10

3. Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting;Vaccine;2024-10

4. Compartment-specific antibody correlates of protection to SARS-CoV-2 Omicron in macaques;iScience;2024-09

5. Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B);International Journal of Infectious Diseases;2024-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3